Research Summary
I trained both as a scientist and as a physician and, throughout my career, I have focused on the treatment and biology of ovarian cancer (OvCa). My Ph.D. thesis was on the role of proteases in ovarian cancer and my clinical fellowship involved a special emphasis on the treatment of patients with this disease. As a surgeon and clinician, I am familiar with the presentation of ovarian cancer in patients, and experience the incredible obstacles we face in its treatment. In the laboratory, I have built the research infrastructure necessary for effective ovarian cancer research. The Lengyel lab has elucidated, at least in part, the first critical steps of ovarian cancer metastasis by paying close attention to the host microenvironment. We have collected the 25 most commonly used ovarian cancer cell lines from all over the world, including those which are chemotherapy resistant. We have established several mouse models for OvCa, and using a genetic mouse model (K-rasG12D/+/Pten-/- -- established by Dr. Tyler Jacks), a syngeneic orthotopic mouse model using mouse OvCa cells (ID8 -- established by K. Roby), and several xenograft ip models using primary and cultured human OvCa cells. I have also established a prospective OvCa tissue bank and, together with 2 gynecologic pathologists, we have assembled 13 tissue arrays including normal tissue, borderline tumor and primary tumor, & corresponding metastasis. As a surgeon, the main focus of my practice is patients with OvCa; therefore, I will be able to enroll a substantial number of patients on the proposed clinical trial and have the infrastructure in place to collect the tissue required for the translational studies. My clinical experience treating ovarian cancer, together with my laboratory, which focuses on OvCa biology, gives me a unique opportunity and obligation to find new treatments that can benefit patients with ovarian cancer.
  • University of Munich, Munich, M.D. M.D. 06/1992
Biosciences Graduate Program Association
  1. Mund A, Coscia F, Kriston A, Hollandi R, Kovács F, Brunner AD, Migh E, Schweizer L, Santos A, Bzorek M, Naimy S, Rahbek-Gjerdrum LM, Dyring-Andersen B, Bulkescher J, Lukas C, Eckert MA, Lengyel E, Gnann C, Lundberg E, Horvath P, Mann M. Deep Visual Proteomics defines single-cell identity and heterogeneity. Nat Biotechnol. 2022 May 19. View in: PubMed

  2. Kurnit KC, Steiner M, Lastra RR, Weroha SJ, Cursio J, Lengyel E, Fleming GF, Conzen SD. High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. Gynecol Oncol Rep. 2022 Jun; 41:100987. View in: PubMed

  3. Javellana M, Hlubocky FJ, Somasegar S, Sorkin M, Kurnit KC, Jani I, Stock E, Mills K, Lengyel E, Lee NK. Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer. JCO Oncol Pract. 2022 06; 18(6):e948-e957. View in: PubMed

  4. Javellana M, Eckert MA, Heide J, Zawieracz K, Weigert M, Ashley S, Stock E, Chapel D, Huang L, Yamada SD, Ahmed AA, Lastra RR, Chen M, Lengyel E. Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer. Cancer Res. 2022 01 01; 82(1):169-176. View in: PubMed

  5. Kumar S, Lee NK, Pinkerton E, Wroblewski KE, Lengyel E, Tobin M. Resilience: a mediator of the negative effects of pandemic-related stress on women's mental health in the USA. Arch Womens Ment Health. 2022 02; 25(1):137-146. View in: PubMed

  6. Somasegar S, Weiss AS, Norquist BM, Khasnavis N, Radke M, Manhardt E, Pennil C, Pennington KP, Eckert MA, Chryplewicz A, Lengyel E, Swisher EM. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Gynecol Oncol. 2021 10; 163(1):130-133. View in: PubMed

  7. Kenny HA, Hart PC, Kordylewicz K, Lal M, Shen M, Kara B, Chen YJ, Grassl N, Alharbi Y, Pattnaik BR, Watters KM, Patankar MS, Ferrer M, Lengyel E. The Natural Product ß-Escin Targets Cancer and Stromal Cells of the Tumor Microenvironment to Inhibit Ovarian Cancer Metastasis. Cancers (Basel). 2021 Aug 04; 13(16). View in: PubMed

  8. Patel M, Wang Y, Bartom ET, Dhir R, Nephew KP, Matei D, Murmann AE, Lengyel E, Peter ME. The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. Cancer Res. 2021 08 01; 81(15):3985-4000. View in: PubMed

  9. Eckert MA, Orozco C, Xiao J, Javellana M, Lengyel E. The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. Cancers (Basel). 2021 Jun 23; 13(13). View in: PubMed

  10. Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, Hoffman A, Chang YF, Blank A, Reardon CA, Kenny HA, Vaisar T, Lengyel E, Greene G, Becker L. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 06 10; 184(12):3163-3177.e21. View in: PubMed

  11. Lindau ST, Makelarski JA, Boyd K, Doyle KE, Haider S, Kumar S, Lee NK, Pinkerton E, Tobin M, Vu M, Wroblewski KE, Lengyel E. Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women. J Womens Health (Larchmt). 2021 04; 30(4):502-513. View in: PubMed

  12. Kurnit KC, Fleming GF, Lengyel E. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021 01 01; 137(1):108-121. View in: PubMed

  13. Reizine N, Peterson B, Moya S, Wang Y, Tan YCYH, Eng OS, Bilimoria M, Lengyel E, Turaga K, Catenacci DVT. Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. JCO Precis Oncol. 2020; 4. View in: PubMed

  14. Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, Deng WM, Granneman JG, Hildesheim J, Kalluri R, Lau KS, Lengyel E, Lundeberg J, Moscat J, Nelson PS, Pietras K, Politi K, Puré E, Scherz-Shouval R, Sherman MH, Tuveson D, Weeraratna AT, White RM, Wong MH, Woodhouse EC, Zheng Y, Hayward SW, Stewart SA. Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget. 2020 Oct 06; 11(40):3621-3632. View in: PubMed

  15. Alter R, Turaga K, Lengyel E. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? JAMA Netw Open. 2020 08 03; 3(8):e2014184. View in: PubMed

  16. Sackeim MG, Lengyel E. Healthy food for trainees: a call to action. Postgrad Med J. 2021 Nov; 97(1153):740-741. View in: PubMed

  17. Adeleye A, Lengyel E. Care of Transgender Persons. N Engl J Med. 2020 04 09; 382(15):1481-1482. View in: PubMed

  18. Coscia F, Doll S, Bech JM, Schweizer L, Mund A, Lengyel E, Lindebjerg J, Madsen GI, Moreira JM, Mann M. A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. J Pathol. 2020 05; 251(1):100-112. View in: PubMed

  19. Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O, Lengyel E. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res. 2020 04 15; 80(8):1748-1761. View in: PubMed

  20. Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019 Oct 18; 2(1):386. View in: PubMed

  21. Zhang Z, Zhan Q, Eckert M, Zhu A, Chryplewicz A, De Jesus DF, Ren D, Kulkarni RN, Lengyel E, He C, Chen M. RADAR: differential analysis of MeRIP-seq data with a random effect model. Genome Biol. 2019 12 23; 20(1):294. View in: PubMed

  22. Hart PC, Kenny HA, Grassl N, Watters KM, Litchfield LM, Coscia F, Blaženovic I, Ploetzky L, Fiehn O, Mann M, Lengyel E, Romero IL. Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 12 17; 29(12):4086-4098.e6. View in: PubMed

  23. Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386. View in: PubMed

  24. Li G, Eckert MA, Chang JW, Montgomery JE, Chryplewicz A, Lengyel E, Moellering RE. Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. Proc Natl Acad Sci U S A. 2019 10 22; 116(43):21493-21500. View in: PubMed

  25. Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, Fazal S, Chen S, Chiang CY, Chen YJ, Brimacombe KR, Marugan J, Ferrer M, Lengyel E. Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Mol Cancer Ther. 2020 01; 19(1):52-62. View in: PubMed

  26. Dauer P, Lengyel E. New Roles for Glycogen in Tumor Progression. Trends Cancer. 2019 07; 5(7):396-399. View in: PubMed

  27. Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženovic I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728. View in: PubMed

  28. Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MA. Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Sci Rep. 2019 03 26; 9(1):5195. View in: PubMed

  29. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972. View in: PubMed

  30. Chapel DB, Lengyel E, Ritterhouse LL, Lastra RR. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. Int J Gynecol Pathol. 2020 May; 39(3):233-237. View in: PubMed

  31. McGuire S, Kara B, Hart PC, Montag A, Wroblewski K, Fazal S, Huang XY, Lengyel E, Kenny HA. Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecol Oncol. 2019 05; 153(2):405-415. View in: PubMed

  32. Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, Loth R, Lastra R, McGregor SM, Locasale JW, Lengyel E, Romero IL. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 04; 17(4):870-881. View in: PubMed

  33. Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 01 07; 216(1):176-194. View in: PubMed

  34. Javellana M, Hoppenot C, Lengyel E. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol. 2019 02; 152(2):228-234. View in: PubMed

  35. Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements JA, Hutmacher DW. A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials. 2019 01; 190-191:63-75. View in: PubMed

  36. Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16. View in: PubMed

  37. Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9. View in: PubMed

  38. Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, Cao J, Zhang Z, Liu J, Lengyel E, He C. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018 09; 20(9):1074-1083. View in: PubMed

  39. Curtis M, Mukherjee A, Lengyel E. The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends Cancer. 2018 08; 4(8):517-519. View in: PubMed

  40. Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367. View in: PubMed

  41. Lengyel E, Makowski L, DiGiovanni J, Kolonin MG. Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. Trends Cancer. 2018 05; 4(5):374-384. View in: PubMed

  42. Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301. View in: PubMed

  43. Li G, Montgomery JE, Eckert MA, Chang JW, Tienda SM, Lengyel E, Moellering RE. An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nat Commun. 2017 11 24; 8(1):1775. View in: PubMed

  44. Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018 01; 148(1):204-212. View in: PubMed

  45. Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160. View in: PubMed

  46. Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M. A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 06; 22(5):494-506. View in: PubMed

  47. Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266. View in: PubMed

  48. Mukherjee A, Kenny HA, Lengyel E. Unsaturated Fatty Acids Maintain Cancer Cell Stemness. Cell Stem Cell. 2017 03 02; 20(3):291-292. View in: PubMed

  49. Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Kossiakoff AA, Roman BB, Lengyel E, Piccirilli JA. Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 04 01; 77(7):1684-1696. View in: PubMed

  50. Gerhard M, Neumayer N, Presecan-Siedel E, Zanner R, Lengyel E, Cramer T, Ho Cker M, Prinz C. Gastrin Induces Expression and Promoter Activity of the Vesicular Monoamine Transporter Subtype 2. Endocrinology. 2001 Aug 01; 142(8):3663-3672. View in: PubMed

  51. Temkin SM, Lengyel E, Tergas A, Terplan M. Ovarian cancer treatment in black and white women: A comparison of clinico-pathologic factors and outcome. J Clin Oncol. 2008 May 20; 26(15_suppl):16531. View in: PubMed

  52. Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351. View in: PubMed

  53. Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI, Kurachi H, Lengyel E, Kimura T. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res. 2017 01; 15(1):78-92. View in: PubMed

  54. Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739. View in: PubMed

  55. Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, Montag A, Lastra RR, Lengyel E, Mann M. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016 08 26; 7:12645. View in: PubMed

  56. Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 10; 15(10):2282-2293. View in: PubMed

  57. Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD. A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 07; 142(1):169-175. View in: PubMed

  58. Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel E. Erratum: Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2016 Feb 03; 7:10649. View in: PubMed

  59. Peters PN, Schryver EM, Lengyel E, Kenny H. Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp. 2015 12 31; (106):e53541. View in: PubMed

  60. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS. Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 Nov 19; 527(7578):398. View in: PubMed

  61. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79. View in: PubMed

  62. Litchfield LM, Mukherjee A, Eckert MA, Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E, Romero IL. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60. View in: PubMed

  63. Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62. View in: PubMed

  64. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28; 521(7553):489-94. View in: PubMed

  65. Kohlhapp FJ, Mitra AK, Lengyel E, Peter ME. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015 Nov 26; 34(48):5857-68. View in: PubMed

  66. Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015 May 10; 6(13):11342-56. View in: PubMed

  67. Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9. View in: PubMed

  68. Mitra AK, Chiang CY, Tiwari P, Tomar S, Watters KM, Peter ME, Lengyel E. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. 2015 Nov 26; 34(48):5923-32. View in: PubMed

  69. Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res. 2015 Feb 15; 21(4):680-6. View in: PubMed

  70. Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel E. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2015 Feb 05; 6:6220. View in: PubMed

  71. Febbraro T, Lengyel E, Romero IL. Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol. 2014 Dec; 135(3):614-21. View in: PubMed

  72. Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero IL. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10. View in: PubMed

  73. Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28. View in: PubMed

  74. King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA, Hayashi K. WNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015 Jun; 34(26):3452-62. View in: PubMed

  75. Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521. View in: PubMed

  76. White EA, Kenny HA, Lengyel E. Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev. 2014 Dec 15; 79-80:184-92. View in: PubMed

  77. Hunn J, Tenney M, Bishop E, Moore K, Tergas A, Lengyel E, Lee N, Yamada S. Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients. Gynecol Oncol. 2012 Oct; 127(1 Suppl):S5-6. View in: PubMed

  78. Ko SY, Ladanyi A, Lengyel E, Naora H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014 Jan; 184(1):271-81. View in: PubMed

  79. Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O'Halloran TV, Lengyel E. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther. 2013 Dec; 12(12):2628-39. View in: PubMed

  80. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. Oncogene. 2014 Jul 10; 33(28):3619-33. View in: PubMed

  81. Landen CN, Lengyel E. Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2013 Jul; 130(1):6-8. View in: PubMed

  82. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013 Oct; 1831(10):1533-41. View in: PubMed

  83. Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T, Takahashi T, Kumasawa K, Nagata S, Morishige K, Lengyel E, Kurachi H, Kimura T. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression. Am J Pathol. 2013 May; 182(5):1876-89. View in: PubMed

  84. Lengyel E, Fleming S, McEwen KA, Montag A, Temkin SM. Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecol Oncol. 2013 Apr; 129(1):120-3. View in: PubMed

  85. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012 Dec; 2(12):1100-8. View in: PubMed

  86. Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012 Oct; 122(10):3603-17. View in: PubMed

  87. Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20. View in: PubMed

  88. Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7. View in: PubMed

  89. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503. View in: PubMed

  90. Kenny HA, Nieman KM, Mitra AK, Lengyel E. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2011 Jul; 1(2):100-2. View in: PubMed

  91. Romero IL, Lee W, Mitra AK, Gordon IO, Zhao Y, Leonhardt P, Penicka CV, Mui KL, Krausz TN, Greene GL, Lengyel E. The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol. 2012 Jan; 124(1):134-41. View in: PubMed

  92. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25. View in: PubMed

  93. Lengyel E, Nicklas M, Jeevan HS, Geibel C, Steglich F. Pressure tuning of the interplay of magnetism and superconductivity in CeCu2Si2. Phys Rev Lett. 2011 Jul 29; 107(5):057001. View in: PubMed

  94. Buell-Gutbrod R, Ivanovic M, Montag A, Lengyel E, Fadare O, Gwin K. FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. Pediatr Dev Pathol. 2011 Sep-Oct; 14(5):391-5. View in: PubMed

  95. Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter ME. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012 Apr 15; 130(8):1787-97. View in: PubMed

  96. Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51. View in: PubMed

  97. Temkin SM, Turner JR, Lengyel ER. Acute inflammatory reaction following placement of sodium hyaluronate-carboxymethylcellulose barrier in a young woman undergoing gynecologic surgery: a case report. J Reprod Med. 2011 Jan-Feb; 56(1-2):71-4. View in: PubMed

  98. Muehlenweg B, Schnelzer A, Türkmen B, Lengyel E, Reuning U, Graeff H, Schmitt M, Magdolen V. RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. Methods Mol Med. 2001; 39:299-306. View in: PubMed

  99. Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9. View in: PubMed

  100. Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SM. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23. View in: PubMed

  101. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71. View in: PubMed

  102. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31; 30(13):1566-76. View in: PubMed

  103. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep; 177(3):1053-64. View in: PubMed

  104. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME. CD95 promotes tumour growth. Nature. 2010 May 27; 465(7297):492-6. View in: PubMed

  105. Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010 Jan; 12(1):1-10. View in: PubMed

  106. Ko SY, Lengyel E, Naora H. The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Mol Cell Endocrinol. 2010 Apr 12; 317(1-2):112-9. View in: PubMed

  107. Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel E. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96. View in: PubMed

  108. Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, Lengyel E. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51. View in: PubMed

  109. Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel E. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila). 2009 Sep; 2(9):792-9. View in: PubMed

  110. Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung D. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril. 2010 Sep; 94(4):1212-1217. View in: PubMed

  111. Deplazes J, Fuchs M, Rauser S, Genth H, Lengyel E, Busch R, Luber B. Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Hum Mol Genet. 2009 Oct 01; 18(19):3632-44. View in: PubMed

  112. Arimoto-Ishida E, Sakata M, Sawada K, Nakayama M, Nishimoto F, Mabuchi S, Takeda T, Yamamoto T, Isobe A, Okamoto Y, Lengyel E, Suehara N, Morishige K, Kimura T. Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. Endocrinology. 2009 Sep; 150(9):4306-15. View in: PubMed

  113. Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009 Mar 01; 8(5):683-8. View in: PubMed

  114. Lindemann K, Harbeck N, Lengyel E, Resau JH. A special key for unlocking the door to targeted therapies of breast cancer. ScientificWorldJournal. 2008 Sep 21; 8:905-8. View in: PubMed

  115. Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol. 2008 Nov; 111(2):173-8. View in: PubMed

  116. Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Vande Woude G, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009 Jan; 17(1):57-67. View in: PubMed

  117. Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol. 2008 Dec; 111(3):537-9. View in: PubMed

  118. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008 Apr 01; 22(7):894-907. View in: PubMed

  119. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39. View in: PubMed

  120. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008 Apr; 118(4):1367-79. View in: PubMed

  121. Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A, Bruno K, Lengyel E. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem. 2008 Feb 01; 283(5):2822-34. View in: PubMed

  122. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007 Nov 01; 6(21):2585-90. View in: PubMed

  123. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11400-5. View in: PubMed

  124. Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 2007 Jul; 51(1):54-62. View in: PubMed

  125. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72. View in: PubMed

  126. Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer H. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Mol Cancer Res. 2007 May; 5(5):485-96. View in: PubMed

  127. Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84. View in: PubMed

  128. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9. View in: PubMed

  129. Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007 Mar; 104(3):524-8. View in: PubMed

  130. Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1356-65. View in: PubMed

  131. Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8538-48. View in: PubMed

  132. Szavcsur P, Godény M, Bajzik G, Lengyel E, Repa I, Trón L, Boér A, Vincze B, Póti Z, Szabolcs I, Esik O. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol. 2005 Mar; 31(2):183-90. View in: PubMed

  133. Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene. 2004 Dec 16; 23(58):9369-80. View in: PubMed

  134. Kugler MC, Gerhard M, Schnelzer A, Borzym K, Reinhardt R, Schmitt M, Lengyel E. Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. Gene. 2004 Oct 27; 341:189-97. View in: PubMed

  135. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005 Feb 10; 113(4):678-82. View in: PubMed

  136. Chen LM, Lengyel ER, Bethan Powell C. Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecol Oncol. 2004 Jul; 94(1):204-7. View in: PubMed

  137. Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res. 2003 Jun; 9(6):2267-76. View in: PubMed

  138. Besta F, Massberg S, Brand K, Müller E, Page S, Grüner S, Lorenz M, Sadoul K, Kolanus W, Lengyel E, Gawaz M. Role of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor. J Cell Sci. 2002 Oct 15; 115(Pt 20):3879-88. View in: PubMed

  139. Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001 Aug; 82(2):291-8. View in: PubMed

  140. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001 Aug; 7(8):2396-404. View in: PubMed

  141. Gerhard M, Neumayer N, Presecan-Siedel E, Zanner R, Lengyel E, Cramer T, Höcker M, Prinz C. Gastrin induces expression and promoter activity of the vesicular monoamine transporter subtype 2. Endocrinology. 2001 Aug; 142(8):3663-72. View in: PubMed

  142. Lengyel E, Ried S, Heiss MM, Jäger C, Schmitt M, Allgayer H. Ras regulation of urokinase-type plasminogen activator. Methods Enzymol. 2001; 333:105-16. View in: PubMed

  143. Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyel E, Reuning U. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem. 2001 Jul 13; 276(28):26340-8. View in: PubMed

  144. Iesalnieks I, Rentsch M, Lengyel E, Mirwald T, Jauch K, Beham A. JNK and p38MAPK are activated during graft reperfusion and not during cold storage in rat liver transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):931-2. View in: PubMed

  145. Hapke S, Gawaz M, Dehne K, Köhler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E. beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol. 2001 Mar; 21(6):2118-32. View in: PubMed

  146. Dickfeld T, Lengyel E, May AE, Massberg S, Brand K, Page S, Thielen C, Langenbrink K, Gawaz M. Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. Cardiovasc Res. 2001 Jan; 49(1):189-99. View in: PubMed

  147. Hannke-Lohmann A, Pildner von Steinburg S, Dehne K, Benard V, Kolben M, Schmitt M, Lengyel E. Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia. Obstet Gynecol. 2000 Oct; 96(4):582-7. View in: PubMed

  148. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000 Jun 15; 19(26):3013-20. View in: PubMed

  149. Marschall C, Lengyel E, Nobutoh T, Braungart E, Douwes K, Simon A, Magdolen V, Reuning U, Degitz K. UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J Invest Dermatol. 1999 Jul; 113(1):69-76. View in: PubMed

  150. Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem. 1999 Jun 04; 274(23):16377-86. View in: PubMed

  151. Schaller G, Fuchs I, Ebert A, Gstettenbauer M, Herbst H, Lengyel E. [The clinical importance of keratin 18 in breast cancer]. Zentralbl Gynakol. 1999; 121(3):126-30. View in: PubMed

  152. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res. 1996 Nov; 2(11):1879-85. View in: PubMed

  153. Jacob K, Wach F, Holzapfel U, Hein R, Lengyel E, Buettner R, Bosserhoff AK. In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res. 1998 Jun; 8(3):211-9. View in: PubMed

  154. Lengyel E, Somogyi A, Molnár T, Tóth E, Remenár E, Skriba Z, Esik O. [Juvenile aneuploid papillary cancer of the thyroid with pulmonary metastasis]. Orv Hetil. 1998 Mar 22; 139(12):687-90. View in: PubMed

  155. Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene. 1997 May 29; 14(21):2563-73. View in: PubMed

  156. Gum R, Wang H, Lengyel E, Juarez J, Boyd D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene. 1997 Mar 27; 14(12):1481-93. View in: PubMed

  157. Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe W, Pfarr CM, Boyd D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem. 1996 Sep 20; 271(38):23176-84. View in: PubMed

  158. Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem. 1996 Jun 01; 61(3):430-43. View in: PubMed

  159. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996 May 03; 271(18):10672-80. View in: PubMed

  160. Beregi E, Lengyel E, Regius O. Physiological age-related changes: cross-sectional and longitudinal studies. Methods Inf Med. 1993 Apr; 32(3):252-4. View in: PubMed

  161. Lengyel E. Twenty-year longitudinal study on aged people in Budapest. Z Gerontol. 1993 May-Jun; 26(3):156-62. View in: PubMed

  162. Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H, Boyd D. Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res. 1995 Feb 15; 55(4):963-7. View in: PubMed

  163. Gum R, Wang SW, Lengyel E, Yu D, Hung MC, Juarez J, Boyd D. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res. 1995 Jul-Aug; 15(4):1167-72. View in: PubMed

  164. Lengyel E, Klostergaard J, Boyd D. Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim Biophys Acta. 1995 Jul 20; 1268(1):65-72. View in: PubMed

  165. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995 Sep 29; 270(39):23007-12. View in: PubMed

  166. Schaller G, Lengyel E, Pantel K, Hardt W, Mischke D. Keratin expression reveals mosaic differentiation in vaginal epithelium. Am J Obstet Gynecol. 1993 Dec; 169(6):1603-7. View in: PubMed